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Abst rac t~An experimental model of  transplantable myelomonocytic leukemia (WEHI-3B) was 
developed in syngeneic BALB/cwm mice to characterize immune mechanisms in this disease. The 
relative effectiveness of various methods for immunizing mice to transplantable myelomonocytic 
cells was analyzed. When mice were immunized i.p. once a week for 3 successive weeks with cell 
preparations (10 T) inactivated by formalin they died at a faster rate than nonimmunized controls. 
When complete Freund's adjuvant was used to enhance the protective response immunized mice 
also died at a faster rate than the controls. If  mice were immunized with various ratios of  X- 
irradiated and viable tumor cells survival time was not increased. The most consistent result was 
accelerated death in the various experimental groups. When mice were immunized once weekly 
with X-ray inactivated cells (5000 R) for 3, 5 o r 8  successive weeks, the survival frequency was 
approximately the same (70-80%) in all three test groups. However, animals immunized 5 times 
withstood a higher challenge dose of tumor cells than those immunized 3 times. The spacings 
between immunizing doses and challenge appeared to significantly affect the efficacy of  immuniza- 
tion. The age of mice had a significant effect on the protective response. When mice 6 weeks of age 
or younger were immunized the survival frequency was < 30~o, compared to 70--80~ in mice 
7 weeks to 8 months of age. Considered together the results of these studies show that tumor cells 
of the WEHI-3B line of transplantable myelomonocytie leukemia are similar to syngeneic P1798 
transplantable lymphoma and the various BALB plasmacytomas in that they are only weakly 
immunogenic in the BALB/c strain. The results also suggest that the immunologic response of 
BALB/c mice to weakly antigenic tumors is under strong negative regulation. 
INTRODUCTION 
ACUTE myelogenous leukemia is one of the most common forms of leukemia in adults. 
Since pure granulocytic or monocytic leukemia is uncommon, and because acute myelo- 
genous leukemia involves both types of cell populations and their progenitors, the term 
acute myelomonocytic leukemia (AMML) has been used to signify that the disease involves 
a diversity of cell populations. The papers by Hayhoe and Cawley [10], and Saarni and 
Linman [29], discuss the complexities of nomenclature, an issue that cannot be considered 
in detail here. The important point is that the diversity of malignant cell populations 
involved in the pathogenesis of the disease has significantly limited the effectiveness of 
various chemotherapeutic regimens [2]. Paradoxically, there is also evidence indicating 
[reviewed in 19] that AMML is more responsive to immunotherapy than acute lymphocytic 
leukemia (ALL). This paradox may be accounted for in a number of ways: the immune 
response in AMML may recognize an antigen that is common to the diverse cell types 
found in the disease, tumor cell kill may be nonspeeific, AMML is not as destructive to 
lymphoid tissues as ALL and therefore is not as immunologically debilitating, etc. To 
Abbreviations; AMML, Acute myelomonocytic leukemia; ALL, Acute lymphocytic leukemia; MESS, 
M611er's balanced salt solution; FSP, Formalin inactivated WEHI  cells of the splenic transplant line; 
FIP, Formalin inactivmed WEHI cells of the peritoneal transplant line; CFA, Complete Freund's adjuvant. 
* This work was supported by grant ACS-CH-84 from The American Cancer Society. 
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discriminate among these possibilities basic data are needed on the nature of the immune 
response to AMML and the protective mechanisms involved. 
Although there is an extensive literature on the immune response to various lymphoid 
neoplasms [13] in mice, corresponding information on AMML is largely lacking. Transplant- 
ation models of the disease have been confined largely to the rat. The model of myelomono- 
cytic leukemia (L5222) in syngeneic BDIX rats described by Hoelzer [11] is a particularly 
acute disease (102 leukemic cells are lethal in 12-13 days) and has been used primarily for 
pharmokinetic studies [9]. The transplantable "myeloblastic leukemia" in Donryu rats 
described by Aoshima and Ishidate [1] also is highly malignant (103 leukemic cells are lethal 
in 13-18 days). Unfortunately, the various cloned transplantation lines studied in this model 
are unstable on serial passage [1]. The only detailed immunologic studies of myelomono- 
cytie leukemia in the rat that could be found were those of Wrathmell and Alexander [34] 
who were unable to immunize syngeneic August rats to the highly lethal (102 leukemic cells 
killed syngeneic rats in 14-23 days) SAL line of transplantable tumor cells. Van Bekkum and 
Hagenbeek recently described [32] a transplantable model of promyelomonocytic leukemia 
in BN rats that may be more suitable for immunologic studies. In this model there was a 
linear relationship between the log~o of viable leukemic cells injected and the time in days 
until death. Low doses of tumor cells (103 ) required from 40 to 45 days to kill recipient 
animals. Because the tumor is slow growing there is sufficient time to permit the generation 
of a protective immune response. We were able to find only one paper each on transplant- 
able "myeloid leukemia" in the hamster [22] and in the guinea pig [6]. In contrast, there have 
been extensive immunologic studies [20] on a transplantable B cell guinea pig leukemia. 
To analyze immunologic mechanisms in AMML a transplantable model in inbred mice 
would offer a number of important advantages: (1) a variety of inbred mice of different 
genotypes are available so that immunologic mechanisms can be analyzed genetically; 
(2) animals can be produced in the numbers needed for the precise quantification of in vivo 
protective mechanisms [14]; and (3) reagents are available to evaluate the role of C-type 
viruses in the pathogenesis of the disease [23]. Preisler et aL [26] and Husseini et aL [12] 
have used RFM transplantable "myeloid leukemia" in RFM/UN mice for pathophysio- 
logic and pharmokinetic studies. This experimental disease appears to be primarily a 
"granulocytic" leukemia. 
The only description in the literature of acute myelomonocytic leukemia in mice that we 
could find is the WEHI model reported by Warner et aL [33]. The original WEHI tumor 
served as the source [33] of four sublines designated A, B, C and D. The A and D sublines 
were chloromas. The B and C sublines were similar to those in humans in a number of respects 
[33]. To develop a transplantable model of the disease suitable for immunologic studies we 
characterized in detail [21] the hematologic and histopathologic properties of the WEHI-3B 
cell subline, thus confirming and extending the original findings of Warner et aL [33]. Three 
sublines of the WEHI-3B line were developed by us [21]. The subcutaneous (SQ) transplant 
line served as a model for solid tumor growth. The intraperitoneal (IP) and splenic (SP) 
lines served as models of diffuse tumor growth. All three sublines are stable on serial trans- 
plantation and the time in days until death is a linear function of the log~o of viable tumor 
cells injected into syngeneic BALB/c mice [21]. All three sublines approximate single cell 
kill and are lethal in 20-30 days [21]. 
The current report is the first in a series of papers dealing with the nature of the protective 
immune response of BALB/c mice to myelomonocytic leukemia. Most of the studies have 
been carried out with the IP line of WEHI tumor cells. Unlike the Friend virus induced 
myeloid leukemias [8], WEHI tumor cells are only weakly immunogenic. This report 
defines the narrow range over which immunization elicits a protective response. 
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M A T E R I A L S  A N D  M E T H O D S  
Mice 
Inbred mice of the BALB/cwm strain (referred to as BALB mice hereafter) were obtained from our 
breeding stocks. The lineage of the strain and hematologic properties of the mice were described previously 
[24]. Female mice were used for all experiments unless stated otherwise. 
Transplantable WEHI-3B myelomonocytic leukemia 
The WEHI-3B line was obtained from Dr. D. Metcalf of the Walter and Eliza Hall Institute of Medical 
Research, Melbourne, Australia. On receipt the subcutaneous tumor was transplanted immediately into our 
strain of mice. The methods used to develop the subcutaneous (SQ), splenic (SP) and intraperitoneal (IP) 
sublines were described previously [21]. The SP subline was derived from the subcutaneous tumor by the 
intraperitoneal injection of a 20% suspension of tumor cells. Thereafter spleen cells from mice moribund 
from leukemia were used for serial passage by the i.p. route. Because the original sublines of  WEHI employed 
by Warner et al. [33] underwent significant variation on serial passage in their hands, we serially passed the 
SP line 25 times to adapt it fully to the splenic growth form. Monodisperse spleen cell suspensions of  the SP 
subline were washed twice in a balanced salt solution designated MBSS [17]. Viable cell counts were done 
by the Trypan Blue dye exclusion technique. For  routine passage 106 viable cells were injected i.p. The IP 
subline was derived from mice that had been inoculated with passage 27 of  the SP subline. However, perito- 
neal cells obtained from mice moribund from leukemia were used for serial passage by the i.p. route instead 
of spleen cells. For  routine passage 6 ml of  MBSS were injected i.p. into mice moribund from leukemia, the 
abdominal cavity was gently massaged, and the fluid withdrawn with an 18 gauge needle and syringe. Cells 
were washed twice and counted. Viability consistently was 95-100 %. Results from dose-response, hemato- 
logic and histopathologic studies were reported [21]. 
Formalin inactivated cells 
Cells of the IP or SP sublines were inactivated with formalin. Fresh tumor cell suspensions were made 
containing 2 x 107 cells per ml of MBSS. A stock formalin solution was made by diluting 37.4 % (g]100 ml) 
of analytical grade formaldehyde 10-fold in MBSS. A fresh working solution was prepared by diluting the 
stock formalin 1:250 in cold (4°C) MBSS. Tumor cells (2× l0 T per ml) were mixed with an equal volume of 
the diluted formalin solution and incubated at 4°C for 18 h. 
X-irradiated cells 
Cells were inactivated as described previously [14]. Thus, cells in 10 ml aliquots (107-10 a per ml of MBSS) 
were dispensed into 60 mm dishes and exposed to X-rays generated by a Coronado X-Ray Therapy Machine 
(Westinghouse Corp.). A dose of 537.5 R/rain was delivered at room temperature for 9.3 rain (5000 R) at a 
distance of 24 cm (X-rays generated at 200 kV, 15 mA, using a 1 mm AI filter). 
Complete Freund' s adjuvant 
WEHI cells (2 x 107 per ml) inactivated by formalin or X-irradiation as described above were emulsified 
in an equal volume of complete Freund's adjuvant (Difco Laboratories, Detroit, MI). 
Admixtures o f  viable and X-irradiated cells 
The methods used to prepare admixtures of  viable and X-irradiated cells were described previously [15]. 
In these experiments only the IP subline of WEHI cells were used. Viable and X-irradiated IP cells were 
mixed in various proportions (Table 3) immediately before 1 ml of the admixture was injected i.p. 
Statistical methods 
Survival data were analyzed as described previously [15, 16] using the Michigan Interactive Data Analysis 
System (MIDAS) which is a subroutine of the Michigan Terminal System. However, in immune mice the 
survival times in days was not normally distributed. Therefore, differences in survival times in days were 
analyzed using nonparametric multisample comparisons as described by Conover [4]. The Mann-Whitney 
test was used for comparisons of two independent samples. The Kruskal-Wallis test was employed when 
three or more samples were compared. Differences in survival frequencies were analyzed by the chi-squaxe 
test as described by Dixon and Massey [5]. 
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Failure to elicit a protective response with formalin inactivated WEH1 cells 
In previous studies [15, 16] we were able to demonstra te  that  weakly antigenic tumor  cells 
elicited a protective response providing that  an appropr ia te  dose-regimen o f  formalin 
inactivated cells was used for  immunizat ion.  The objective o f  the current experiments was to 
determine whether  BALB mice could be immunized similarly to a low challenge dose 
(103 viable cells) o f  W E H I  tumor  cells. Initial experiments were done with the IP  and SP 
t u m o r  t ransplant  lines because o f  the possibility that  they might  differ significantly in 
immunogenici ty .  D a t a  representative o f  a large number  o f  experiments are presented in 
Table 1. Mice that  received one or  two i.p. injections o f  formalin inactivated SP (FSP) cells 
TABLE 1. FAILURE TO ELICIT A PROTECTIVE RESPONSE WITH FORMALIN INACTIVATED WEHI 
CELLS 
Challenger Median survival 
Expt. No. Treatment* dose Survivors time (days) P value, 
1 MBSS-1X 103 0/10 22.7 
FSP-1X 103 0/9 22.2 0.10 
MBSS-2X 104 0/10 20.2 
FSP-2X 104 0/5 19.0 0.10 
2 MBSS-3X 104 0/5 18.3 
FSP-3X 104 0/5 16.2 0.02 
MBSS-3X 10 a 0/I0 21.9 
FSP-3X 103 0/10 19.2 0.004 
FSP-3X - -  5/5 - -  
3 MBSS-3X 103 0/12 22.4 
FIP-3X 103 0/12 21.1 0.03 
FIP-3X - -  9/9 - -  
* Six week old mice were given 1, 2 or 3 serial i.p. injections (spaced 1 week apart) of formalinized WEHI 
cells of the splenic (FSP) or peritoneal (FIP) passage lines. Tumor cells were inactivated by incubation in 
1:5000 formalin for 18 h at 4°C. Control mice received an injection of balanced salt solution (MBSS) in 
place of inactivated tumor cells. 
"l" One week after the last immunization mice were challenged by the i.p. injection of either 103 or 10" 
viable tumor cells of the appropriate passage line. 
Differences in median survival times were analyzed by the Mann-Whitney test as described in the text. 
spaced 1 week apar t  died at the same rate as control  mice (experiment 1). When  mice re- 
ceived three weekly injections o f  formalinized cells o f  either the SP or  IP  subline they 
consistently died at a faster rate than the nonimmunized  controls  (experiments 2 and 3). 
To test whether  formalin t reatment  inactivated t umor  cells, mice received identical im- 
munizat ions  with formalinized cells but were not  challenged (experiments 2 and 3). All o f  
the mice survived immunizat ion.  Since the IP  and SP sublines approximate  single cell kill [21] 
these results provide reasonable evidence that  mice were not  dying f rom viable cells con- 
tained in the formalinized preparations.  
Effect of  complete Freund's adjuvant (CFA) on the protective immune response 
To test whether C F A  augmented a protective response, W E H I  tumor  cells o f  the IP  
passage line were emulsified in C F A  and injected subcutaneously in each o f  four  sites 
(2.5 x 106 cells/site). The cells used for immuniza t ion  were inactivated either with formalin 
as described above or  with 5000 R o f  X-irradiat ion.  Cells were injected proximal to the 
draining inguinal or  axillary lymph nodes o f  each leg to assure that  the lymphoid  cells in 
each o f  the draining nodes would have a maximal  oppor tun i ty  to be sensitized by antigen. 
Injections were made once a week for 3 successive weeks. The results show (Table 2) that  the 
mice which received injections o f  C F A  alone, or  tumor  cells suspended in CFA,  died at a 
faster rate than the controls.  
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TABLE 2. EFFECT OF CFA ON THE PROTECTIVE RESPONSE TO WEHI  
CELLS 
Median survival 
Treatment* Survivors time (days) P valuer 
MBSS 0/10 22.5 
MBSS :CFA 0/10 20.0 0.003:~ 
XIP 1 / 10 23.0 
X I P : CFA  0/10 20.3 0.05:~ 
FIP 0/10 23.5 
FIP-CFA 0/10 20.3 0.0004~/ 
* Only tumor cells of the IP passage line were used. They were inactivated with X-irradiation (XIP) or 
formalin (FIP) as described in the text. The immunogenieity of cells emulsified in CFA was compared with 
controls in which CFA was deleted. Preparations (2 x 106 cells) were injected s.q. into each leg proximal to 
the draining inguinal or axillary lymph nodes. Injections were made once a week for 3 successive weeks. One 
week after the last injection mice were challenged by the intraseapular injection of 104 viable tumor cells. 
~" See footnote :~, Table 1. 
.* Compared to the preparation without CFA. 
TABLE 3. FAILURE TO ELICIT A PROTECTIVE RESPONSE WITH ADMIXTURES OF VIABLE 
AND X-IRRADIATED WEHI  CELLS 
Median survival 
Group  Treatment* Survivors time (days) P value'l" 
1 3V :0X 0/12 23.8 
3V:3X 0/12 24.3 NS 
3V:4X 0/11 23.8 NS 
3V :5X 0/12 22.8 0.03 
3V:6X 0/12 21.9 < 0.001 
3V :7X 0/8 22.3 NS 
2 4V :0X 0/l 2 23.8 
4V :3X 0/12 20.9 0.02 
4V :4X 0/12 21.9 0.03 
4V :5X 0/12 21.4 0.02 
4V :6X 0/12 20.9 0.01 
4V:7X 0/8 18.6 < 0.01 
3 5V:0X 0/12 19.4 
5V:3X 0/12 19.1 NS 
5V:4X 0/12 19.1 NS 
5V :SX 0/11 18.4 NS 
5V:6X 0/12 18.1 NS 
5V :7X 0/8 17.9 0.04 
4 6V:0X 0/12 16.6 
6V :3X 0/12 17.0 NS 
6V:4X 0[12 16.3 NS 
6V :5X 0/12 16.6 NS 
6V:6X 0/11 15.8 NS 
6V :7X 0/8 15.6 0.02 
5 7V:0X 0/8 14.5 
7V:4X 0/7 13.9 NS 
7V:5X 0/8 13.3 NS 
7V :6X 0/8 13.2 NS 
7V :7X 0/8 13.3 NS 
* WEHI  tumor cells of the IP line were inactivated by 5000 R of X-irradiation. Each mouse in each test 
group received a single 1 ml i.p. injection that contained the log 1o number  of  viable (V) or X-irradiated (X) 
cells indicated. One week after immunization all mice were challenged by the i.p. injection of 103 viable 
tumor cells. All mice were 6-8 weeks old when immunized; only females were used. 
t See footnote ~, Table 1. The P values compare each of the data sets with mice that received no (0X) 
irradiated tumor cells; NS, no significant difference. 
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Failure to elicit a protective response with admixtures of viable and X-irradiated WEHI 
tumor cells 
In  previous studies [15, 16] we documented  that  the immune response to weakly antigenic 
malignant  lymphocytes  was superior when admixtures o f  X-irradiated and viable tumor  
cells were used for  immunizat ion.  Since the results presented in Tables 1 and 2 indicated 
that  W E H I  cells were only weakly immunogenic ,  an a t tempt  was made to demonstrate  a 
protective immune  response by the use o f  admixtures o f  killed and viable W E H I  cells for  
immunizat ion.  In  these experiments only t umor  cells o f  the IP  subline were used. To assess 
their X- ray  sensitivity W E H I  cells (109 viable cells contained in 10 ml o f  MBSS) were placed 
in 60 m m  plastic culture dishes and irradiated at a dose o f  537.5 R per min at r o o m  tempera- 
ture. The dose range used was f rom 0 to 15,000 R. Mice in groups  o f  12 were used to test 
X-irradiated cells for  viability. Since a single cell o f  the IP  line is lethal to mice [21] reason- 
ably accurate da ta  were obta ined:  12/12 mice died when cells received 500 R;  1/12 deaths 
at  1000 R;  and 0/12 deaths at X- ray  doses o f  5000, 10,000 or  15,000 R. Thus,  5000 R was 
used as a s tandard to inactivate W E H I  cells. 
TABLE 4. EFFECT OF DOSE-REGIMEN ON THE IMMUNE RESPONSE TO WEHI TUMOR CELLS 
Method of immunization* Survivorst Per cent survivors 
Experiment 1 : a single immunization 
(a) Mice challenged 1 week later 
(b) Mice challenged 2 weeks later 
(e) Mice challenged 3 weeks later 
Experiment 2: two immunizations spaced 
(a) 1 week apart 
(b) 2 weeks apart 
(c) 3 weeks apart 
Experiment 3: three immunizations spaced 
(a) 1 week apart 
(b) 2 weeks between first and second 
(c) 1 week between first and second with a 2 week skip 
between second and third 
(d) 3 weekly immunizations; challenge 2 weeks after the 
last immunization 
Experiment 4: five immunizations spaced 1 week apart 
Experiment 5: eight immunizations spaced 1 week apart 
0/20 (2) 0 
0/10 (1) 0 
0/20 (2) 0 
13/40 (3) 33 
38/50 (4) 76 
22/39 (3) 56 
105/157 (8) 67 
7/10 (1) 70 
lO/tO (1) 100 
9/22 (2) 41 
21/25 (2) 84 
18/22 (2) 82 
* Mice 8-12 weeks old were used for experiments 1, 2 and 3. In experiment 4 one group was 5 weeks old 
and the other 8 weeks old at the start of serial immunizations. Mice received from two to eight serial i.p. 
injections of 107 X-irradiated (5000 R) WEHI cells spaced as indicated. Mice were challenged by the i.p. 
injection of 10 a viable WEHI cells I week after the last immunization or as noted in the table. 
~" The numbers in brackets indicates the number of replicate experiments. 
In  Table 3 various propor t ions  o f  viable (V) and X-irradiated cells (X) were combined so 
that  1 ml o f  cell suspension contained the indicated numbers.  None  of  the preparat ions  
e l i c i t eda  protective response. The most  consistent result was accelerated death. The effect 
was mos t  marked in the g roup  2 animals. 
lmmunogenicity of  X-irradiated cells given in various dose regimens 
Multiple injections o f  inactivated cells are required to elicit a protective response with 
weakly antigenic tumors  [15, 16, 30]. Systematic studies therefore were carried out  to deter- 
mine the op t imum dose-regimens for  immunizing mice to X-irradiated cells o f  the IP  line o f  
W E H I  tumor  cells. Table 4 shows the results when mice received f rom one to eight serial 
injections o f  107 X-irradiated W E H I  cells spaced in various ways, and then were challenged 
at various times after the last immunizat ion.  When  mice received a single i.p. injection o f  
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107 X-irradiated W E H I  cells none survived. An increase in survival time could be detected 
only if mice were challenged 2-3 weeks after immunization (data not shown). When mice 
received two immunizations spaced 1 week apart, survival approximated 33 ~ (experiment 
2a). When the second immunization was given 2-3 weeks after the first, survival was in- 
creased. In experiment 3 mice were given three immunizations spaced in various ways. The 
results of  experiments (a) and (b) were essentially the same. The results of  (d) differed from 
(a) and (b) or (c). Our experience with this model suggests that (c) was not different from (a) 
and (b). The mice in group d had a lower survival frequency than those in a, b and c, thus 
suggesting that immunity waned rather rapidly after the last immunization. The table 
(experiments 4 and 5) also shows that mice given five to eight serial immunizations did not 
have a survival frequency greater than those given three immunizations. Overall, the most 
consistent results were obtained when mice were immunized 3 times spaced 1 week apart 
and challenged l week after the last immunization (70-80~o survival). Accordingly, this 
technique was adopted as the standard for immunization. 
Level and duration of immunity 
Although the data in Table 4 indicated that the survival frequencies of  mice immunized 
from 3 to 8 times were essentially the same, the possibility existed that the immune response 
differed quantitatively. To document whether such a difference existed, mice were immunized 
weekly 3-5 times with X-irradiated tumor cells and challenged 1 week after the last immuniz- 
ation with from 103 to 105 viable WEHI  tumor cells. The data in Table 5 show that the level 
of  resistance elicited by five serial immunizations was higher than that observed when mice 
received three serial immunizations. Table 6 shows that the maximum level of  immunity 
(approximately 85 ~o survival) persisted for only 1-3 weeks after mice were immunized 3 
times at weekly intervals. 
TABLE 5. LEVEL OF RESISTANCE INDUCED BY IMMUNIZATION Vv'ITH X-IRRADIATED 
WEHI TUMOR CELLS 
Number of weekly* Challenger 
injections dose Survivors~: Per cent survivors 
3 10 a 22/27 (2) 81 
5 103 13/15 (1) 87 
3 104 7/27 (2) 26 
5 104 12/15 (1) 80 
3 105 2/27 (2) 7 
5 105 5/15 (1) 33 
* Ten to twelve week old female mice given three or five weekly injections of 10 ~ X-irradiated WEHI 
cells were challenged 1 week after the last immunization as indicated. 
t Mice were challenged by the i.p. injection of 103-105 viable WEHI cells as indicated. 
The number of replicate experiments is shown in brackets. 
TABLE 6. PERSISTENCE OF IMMUNITY 
Time of challenge* 
(weeks) Survivors't" Per cent survival P value:~ 
1 23/27 (2) 85 
2 7/12 (1) 58 0.15 
3 8/12 (1) 67 0.37 
4 15/27 (2) 55 0.04 
10 7/15 (1) 46 0.02 
* Female mice 8-10 weeks old received three serial i.p. injections spaced 1 week apart of 107 X-irradiated 
WEHI cells and were challenged i.p. as indicated with 103 viable cells. 
t" The number of replicate experiments is shown in brackets. 
~. The chi-square test was used to compare all groups of mice with those challenged at 1 week. 
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Effect o f  age and sex on the immune response 
During the experiments described above it was observed that both the age and sex of 
mice appeared to affect the immune response to X-irradiated W E H I  tumor cells. Experi- 
ments were therefore carried out to define the magnitude of  such effects. Table 7 shows that 
4-6 week old mice were less effective in developing a protective response than those 7 weeks 
to 8 months of  age. Differences in the response of  mice among the 7 week to 8 month age 
groups did not differ statistically. Overall 143/184 mice in these groups survived immuniz- 
ation and challenge (approximating an 80 ~ survival frequency). The sex of  mice did not 
affect survival frequency, viz., 27/40 female survivors (68~o) compared with 19/40 male 
survivors (48 ~o) in two replicate experiments (P = 0.07). 
TABLE 7. EffECT OF AGE ON THE IMMUNE RESPONSE OF BALB MICE TO 
WEHI TUMOR CELLS 
Age of mice at the first 
immunizing injection* Survivorst Per cent survival~ 
4 weeks 1/14 (1) 7 
6 weeks 14/50 (3) 28 
7 weeks 8/12 (1) 67 
8 weeks 17/22 (2) 77 
10 weeks 52/67 (4) 78 
11 weeks 6/9 (1) 67 
12 weeks 33/45 (3) 73 
4 months 15/15 (1) I00 
8 months 12[15 (1) 80 
* Mice received three serial i.p. injections of 107 X-irradiated WEHI tumor cells spaced 1 week apart and 
were challenged by the i.p. injection of 103 viable WEHI cells 1 week after the last immunization. 
t The number of replicate experiments is shown in brackets. 
:l: The data for mice 7 weeks to 8 months of age did not differ significantly (P = 0.4). The results for 4 week 
old mice did not differ from those for 6 week old mice (P = 0.1). Results for the 4-6 week old mice differed 
significantly (P = 0.000) from those for the 7 week to 8 month old group. 
DISCUSSION 
The results reported here indicate that the WEHI  line of  transplantable myelomonocytie 
leukemia is only weakly immunogenic in syngeneic BALB/cwm mice. It therefore differs 
significantly from the Friend-Moloney-Rauscher virus induced myeloid or lymphoid 
malignancies which elicit a strong protective immunologic response [7, 8]. For example, 
when mice were immunized with formalin inactivated cells (Table 1) and then challenged 
with a minimum dose (10 a) of viable tumor cells, they died at a faster rate than nonimmun- 
ized controls. Table 2 shows that when mice were immunized with formalin or X-ray in- 
activated ceils emulsified in CFA and then were challenged, they also died at a faster rate 
than the nonimmunized controls. This result occurred despite the fact that multiple injec- 
tions of  inactivated cells were made by the subcutaneous route in a way to assure that 
draining lymph node cells were exposed to antigens. In similar studies of  a weakly immuno- 
genie transplantable lymphoma (line Ib leukemia in syngeneic C58 mice) we documented 
[16] that a strong protective response could be elicited if mice were immunized with a single 
i.p. injection of  an admixture containing 107 X-irradiated and 103 viable tumor cells. When 
this technique was used in attempts to immunize BALB mice to WEHI  cells (Table 3) again 
the most consistent response was accelerated death. 
The results summarized in Tables 1-3 could be interpreted in several ways: (1)if  WEHI  
cells were only weakly immunogenic and consisted of  populations of different antigenicities, 
a broadly protective response might not be elicited; (2) in the W E H I  model the methods used 
to elicit a protective response to a weak tumor antigen may have been ineffective because 
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the techniques employed may have preferentially elicited a suppressive rather than a pro- 
tective response [3]; and (3) the poor protective response seen in Tables 1-3 may not have 
been a characteristic of myelomonocytic leukemia, but was instead an example of how a host 
of a given genotype may manifest an immune response to weakly antigenic tumor cells, i.e. 
one in which the predominant response is one of negative regulation [3]. As discussed 
below, a number of lines of evidence favor hypothesis 3. 
Our initial interpretation of the results presented in Tables 1-3 was that there was an 
active immune response. However, it was one in which suppressive mechanisms predomin- 
ated, thus resulting in accelerated death. A systematic study therefore was done with X-ray 
inactivated cells (5000 R)which sought to identify a dose-regimen of immunization that 
preferentially elicited a protective rather than a suppressive response (accelerated death). 
Table 4 presents representative results from an extensive series of experiments [31]. When 
mice received a single immunization and were challenged one or three weeks later, 
there were no survivors. However, when mice were challenged 2 or 3 weeks after immuniz- 
ation survival time was increased. This suggested that the timings of immunization and 
challenge were of key importance in eliciting a protective response. We therefore scheduled 
immunizations and challenge in such a way that protective, rather than suppressive, re- 
sponses might be preferentially activated. In carefully controlled experiments it was 
possible to demonstrate a superior survival frequency when two immunizations were spaced 
2 or 3 weeks apart (Table 4, experiments 2b and c). In experiments in which mice received 
three immunizations spaced in various ways (Table 4) limits in the statistical reproducibility 
of the assays did not permit a clear-cut distinction to be made among groups (a), (b) and (c) 
unless enormous numbers of mice were used, i.e. under experimental conditions where 
survival was consistently high (70-100 %). This limitation also applied to experiments 4 and 
5 where mice received either five or eight serial immunizations. 
Our impression that the immune response of BALB mice to WEHI cells was under 
strong negative regulation was strengthened by the results presented in Table 5. Although 
these data clearly show that mice immunized serially 5 times at weekly intervals withstood 
a higher challenge dose of viable tumor cells than those immunized 3 times, the level of 
immunity elicited was not particularly high compared to similar studies done with weakly 
immunogenic line Ib lymphoma cells in syngeneic C58 mice [15, 16]. In the later model a 
single injection of formalin or X-ray inactivated cells protects mice to a l0 T LD~oo challenge 
dose of tumor cells and immunity persists at high levels for more than 30 weeks [14]. In the 
WEHI model immunity begins to wane 1-2 weeks after the last immunizing injection 
(Table 4, experiment 3d and Table 6). Further support for the ,~lew that the protective 
response to WEHI cells may be under strong negative regulation was obtained by the data 
summarized in Table 7. It was not possible to elicit a significant protective response in mice 
less than 7 weeks of age, a finding consistent with the observation [18] that suppressive 
mechanisms are strongest in young immunologically immature mice. In preliminary experi- 
ments we also have found [31] that mice could be effectively immunized if they were pre- 
treated with an appropriate dose of cyclophosphamide, a procedure that inactivates sup- 
pressor T cells [27]. Considered together the described results indicate that the protective 
immune response of BALB/cwm mice to WEHI cells is under strong negative regulation 
and may be suppressor cell mediated. 
At first glance our data also suggest that WEHI myelomonocytic leukemia cells are 
distinguished by the fact that they are only weakly immunogenic and that this may be an 
important causal factor in the pathogenesis of this disease. Although such an interpretation 
may be correct, a consideration of several representative tumor models in the BALB/c 
strain cautions against such a restrictive interpretation and leads to a more general hypo- 
thesis: in the BALB/c strain the predominant response to weak tumor antigens may be one 
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of strong negative regulation. A number of lines of evidence are consistent with the more 
generalized hypothesis. For example, Prager et  al. found [25] that P1798 lymphoma cells 
were only marginally immunogenic in syngeneic BALB/c mice even after cells were modified 
chemically in a variety of ways to enhance their immunogenicity. Protection to low doses of 
challenge tumor cells (103 or 104 ) could be achieved only when mice received 12-13 serial 
i.p. injections of modified cells at weekly intervals. In their review of the immunogenicity 
of various plasmacytomas induced in BALB/c mice by mineral oil or by other methods, 
R611inghoff et  al., [28] pointed out that such tumors are only weakly antigenic and that a 
protective response is difficult to elicit even when mice receive multiple injections of in- 
activated cells at weekly intervals. 
In conclusion, it may be helpful for future work to consider that the protective responses 
of inbred mice to weak tumor antigens is divisible into two broad categories. One class of 
response is exemplified by the line Ib-C58 experimental model [15, 16] where the immune 
response is not under strong negative regulation. In this class of responses the problem is 
mainly one of finding the dose-regimen of immunization that elicits a high level of protection. 
The LI210 model of transplantable lymphoma in DBA mice also appears to fit into this 
category. In the second class suppressive mechanisms predominate. In such models the 
mouse genotype strongly regulates a negative response and suppressive immune mechanisms 
predominate, i.e. immunity is difficult to elicit, does not reach high levels, and does not per- 
sist at high levels. The P1798 transplantable lymphoma [25] and the various BALB/c plasma- 
cytomas [34] may be representative of this type of response. The WEHI model of AMML also 
appears to fit into this category. 
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